Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Neurocrine Biosciences.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Neurocrine Biosciences
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130
Telephone
Telephone
1-858-617-7600
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Through collabraotion, Neurocrine will to focus on the development and commercialization of VY-FXN01, which helps to restore FXN protein levels. It is being evaluated in the treatment of Friedreich’s ataxia.


Lead Product(s): VY-FXN01

Therapeutic Area: Genetic Disease Product Name: VY-FXN01

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Voyager Therapeutics, Inc

Deal Size: $1,865.0 million Upfront Cash: $165.0 million

Deal Type: Collaboration February 26, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

NBI-74788 (crinecerfont) is an investigational, oral, selective CRF1 antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia.


Lead Product(s): Crinecerfont

Therapeutic Area: Genetic Disease Product Name: NBI-74788

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ingrezza (valbenazine) a new sprinkle formulation of capsules PDUFA target action date of April 30, 2024 and it is selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for the treatment chorea associated with Huntington's disease (HD).


Lead Product(s): Valbenazine Tosylate

Therapeutic Area: Neurology Product Name: Ingrezza

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

NBI-74788 (crinecerfont) s an investigational, oral, selective CRF1 antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia.


Lead Product(s): Crinecerfont

Therapeutic Area: Genetic Disease Product Name: NBI-74788

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.


Lead Product(s): NBI-1117570

Therapeutic Area: Neurology Product Name: NBI-1117570

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Sosei Heptares

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

INGREZZA® (valbenazine) Capsules is the selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD).


Lead Product(s): Valbenazine Tosylate

Therapeutic Area: Neurology Product Name: Ingrezza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.


Lead Product(s): Undisclosed

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Peptide

Recipient: Sentia Medical Science

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration February 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the collaboration, Neurocrine will receive worldwide rights to Voyager’s GBA1 gene therapy program for Parkinson’s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare CNS targets.


Lead Product(s): GBA1-based Gene Therapy

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Voyager Therapeutics, Inc

Deal Size: $1,675.0 million Upfront Cash: $175.0 million

Deal Type: Collaboration January 09, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The sNDA for valbenazine for the treatment of chorea associated with Huntington disease is supported by data from two clinical studies, including the Phase 3 study and the on-going KINECT-HD2 open-label rollover study, with more than 150 patients with Huntington disease.


Lead Product(s): Valbenazine Tosylate

Therapeutic Area: Genetic Disease Product Name: Ingrezza

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 22, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

NBI-827104 is an investigational, potent, selective, and orally active brain-penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) in development for the potential treatment of EE-CSWS.


Lead Product(s): NBI-827104

Therapeutic Area: Neurology Product Name: NBI-827104

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY